Weekly Evidence Report



Health Technology Assessment Philippines

31 October- 6 November 2020

Overview

The following report presents summaries of evidence the Department of Health (DOH) - Health Technology Assessment (HTA) Unit reviewed for the period of 31 October to 6 November 2020. The HTA Unit reviewed a total of 13 studies for the said period.

Evidence includes 2 studies on Epidemiology; 2 studies on Transmission; 3 studies on Drugs; 0 studies on Vaccines, 2 studies on Equipment and Devices; 0 studies on Traditional Medicine; and 2 studies on Preventive & Promotive Health.

The following report notes that 3 studies have not been peer-reviewed, each highlighted accordingly.



Sections

⊏þ	uen	IIOIC	JRA	
				_

Transmission

Drugs

Vaccines

Equipment & Devices

Medical & Surgical Procedures

Traditional Medicine

Preventive & Promotive Health

Evidence on Epidemiology

Local COVID-19 Tracker: https://www.doh.gov.ph/covid19tracker
Local COVID-19 Case Tracker: https://www.doh.gov.ph/covid-19/case-tracker

Date	Author/s	Title	Journal/ Article Type	Summary
4 Nov 2020	ASEAN Biodiaspora Virtual Center	Risk Assessment for International Dissemination of COVID-19 to the ASEAN Region	ASEAN Biodiaspora Virtual Center (Risk Assessment Report)	 Globally there have been 47.7 million cases with 1.21 million deaths related to COVID-19 The USA currently has the highest percentage of cases 959,225 cases are noted in the ASEAN region with 23,159 deaths
3 Nov 2020	WHO	COVID-19 Weekly Epidemiological Update	WHO (Weekly Epidemiology Report)	 Half of the world's new COVID-19 cases are from EU countries with a 46% increase in deaths compared to the previous week A significant increase in number of cases are noted among the adolescent and young adults and slight increase for aged 0-4 years and 5-14 years old A decrease and stabilization of cases noted in aged 65 and older from 40% to 15% in recent weeks

Evidence on Transmission

Date	Author/s	Title	Journal/ Article Type	Summary
4 Nov 2020	Qifang et.al.	Household Transmission of SARS-COV-2: Insights from a Population-based Serological Survey	MedRxiv (Serosurvey)	 4,524 household members from 2, 267 households aged five years onward were included in a serosurvey conducted April to June 2020 There is a 17.2% (95% CI, 13.6%-21.5%) chance of being infected by a single SARS-CoV-2 infected household member versus 5.1% (95% CI 4.5%-5.8%) from the cumulative extra-household infection risk. There is an increase in infection risk as a person ages from 7.5% (95% CI, 1.3-20.3%) among those aged 5-9 years old to 30.2% (95% CI 14.3%-48.2%) among those of 65 years old and older.

Date	Author/s	Title	Journal/ Article Type	Summary
2 Nov 2020	Huoang, Tung	Systematic review and meta-analysis of factors associated with re-positive viral RNA after recovery from COVID-19	Journal of Medical Virology (Systematic Review & Meta-Analysi s)	 Odds ratio estimates were pooled in the study using random-effect meta-analysis or weighted mean difference (WMD) Hospital duration were shorter for recurrence cases with -1.55 days WMD (95% CI, -2.66 to -0.45). Fatigue (OR 4.06, 95% CI, 1.14-14.4), positive IgM (2.95 OR, 95% CI 1.15-7.61), and positive IgG (3.45 OR, 95% CI 1.58-7.54) were found to be associated with increased risk of recurrence Cases with elevated lactate dehydrogenase (1.08 OR, 95% CI, 0.27-4.37), Elevated C-reactive protein (0.49 OR, 95% CI, 0.27-0.97), Low lymphocyte count (0.64 OR, 95% CI, 0.42-0.97), Steroid use (0.48 OR, 95% CI, 0.25-0.96), and Arbidol use (0.48 OR, 95% CI, 0.25-0.92) had significantly lower cases of recurrence

Evidence on Drugs

Date	Author/s	Title	Journal/ Article Type	Summary
4 Nov 2020	Hunter, et.al.	Benefits and risks of zinc for adults during covid-19:rapid systematic review and meta-analysis of randomised controlled trials	MedRxiv (Systematic Review & Meta-analysis)	 17 english and Chinese databases were used for this living systematic review and meta-analysis of randomized controlled trials. From 123 RCTs, it was seen that compared to placebo, zinc prevented mild to moderate respiratory tract infection at a rate of 5% (95% CI, 1-9) with a number needed to treat of 20

Date	Author/s	Title	Journal/ Article Type	Summary
14 May 2020 Update Published 4 Nov 2020	CADTH	Remdesivir: Evidence Review and Appraisal	CADTH Evidence Review	 Update of including the outcomes of the ACTT-1 Study Remdesivir group median time to recovery was 10 days (95% CI, 9%-11%) compared to 15 days (95%CI 13%-18%) for the placebo group Higher odds of clinical status improvement was noted with the Remdesivir group seen at day 15 (Odds ratio for improvement= 1.5 [95% CI 1.2 to 1.9],adjusted for disease severity) Mortality was noted at 6.7% (95% CI, 4.8%-9.2%) for Remdesivir patients compared to the placebo group with 11.9% (95% CI, 0.36-0.83) All-cause mortality for the Remdesivir group was at 11.4% (95% CI 9.0%-14.5%) versus 15.2% (95% CI, 12.3%-18.6%) for the placebo group
4 Nov 2020	Goldman, et.al.	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19	NEJM (Randomized, open-label Phase 3 trial)	 The study was done on hospitalized confirmed SARS-CoV-2 infection with oxygen saturation of 94% or less in ambient air All patients received 200mg of Remdesivir on day 1 and 100mg once daily on succeeding days The median duration of treatment was 5 days in the 5-day group and 9 days in the 10-day group. A clinical improvement of 2 points from the 7-point ordinal scale was noted on day 14

Evidence on Vaccines

Date	Author/s	Title	Journal/ Article Type	Summary

Evidence on Equipment & Devices

Date	Author/s	Title	Journal/ Article Type	Summary
4 Nov 2020	Javor, et.al.	Deep learning analysis provides accurate COVID-19 diagnosis on chest computed tomography	European Journal of Radiology	 An open source dataset was used with a novel deep learning derived machine learning classifier to analyze its capacity to diagnose COVID-19 using chest CT images. Receiver Operating Characteristics analysis was used in the study An overall accuracy of 0.956 (AUC) on an independent testing dataset (90 patients) with a rule in sensitivity of 84.4% and specificity of 93.3% (p>0.05) and a rule-out sensitivity of 100% and specificity of 60% (p<0.05)
4 Nov 2020	Wang, et.al.	A Novel Primer Probe Set for Detection of SARS-CoV-2 by Sensitive Droplet Digital PCR	MedRxiv (Experimental Study)	 A novel probe was designed to target the N gene and showed that at a quantity of 105 copies/reaction, the mean Ct value was 32.563 with a 91.7% detection rate. The lower limit of detection used in an RT-PCR was 118 copies/reaction. When used with a ddPCR, the lower limit of detection was calculated at 22.4 copies/reaction or 1.12 copies/microliter The novel primer-probe (LZU3) can be used with rRT-PCR and ddPCR with better sensitivity for ddPCR method

Evidence on Medical & Surgical Procedures

Date	Author/s	Title	Journal/ Article Type	Summary
2 Nov 2020	Park et.al.	Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data	Acta Oncologica (Systematic Review & Meta Analysis)	 16 retrospective and prospective studies including a total of 3,558 patients were included in the review. Higher risk of death was found to be associated to active chemotherapy (OR 1.60, 95% CI, 1.14-2.23) versus no active chemotherapy Active targeted therapy, immunotherapy chemoimmunotherapy, or recent surgery had no significant association with the risk of death Meta-analysis of multivariate adjusted OR still noted active chemotherapy to have higher association with risk of death (OR 1.42, 95% CI, 1.01-2.01)
2 Nov 2020	Zhang, et.al.	Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis	Journal of the National Cancer Institute (Systematic Review & Meta-Analysis)	 15 studies included with 3,019 patients in total were reviewed noting an overall case fatality of COVID-19 patients with cancer at 22.4% (95% CI, 17.3%-28.0%) Age (3.57 OR, 95% CI 1.80-7.06), the male sex (2.10 OR, 95% CI 1.07-4.130, and presence of comorbidities (2.00 OR, 95% CI 1.04-3.85) were associated with higher risk of severe events.

Evidence on Traditional Medicine

Date	Author/s	Title	Journal/ Article Type	Summary

Evidence on Preventive & Promotive Health

Date	Author/s	Title	Journal/ Article Type	Summary
4 Nov 2020	HIQA	Rapid review of recommendations from international guidance on the duration of restriction of movements	HIQA (Rapid Review)	 The rapid review of international recommendations from WHO, ECDC, CDC, European Commission and 22 countries was conducted up to a search date of 14 October 2020 7, 10, 0r 14 day restriction of movement for close contact to COVID-19 patients are found depending on jurisdiction 7, 10, 0r 14 day restriction of movement was found as well for travellers depending on epidemiological risk of the origin country Terminology used for movement restriction was found to be confused with self-isolation The review defines self-isolation as confining a confirmed COVID-19 patient from transmission of disease through isolation
4 Nov 2020	HSE Library Evidence Team	What is the current evidence for the effectiveness of using a visor rather than a surgical face mask in preventing the transmission of COVID-19 in a healthcare setting?	HSE Library (Summary of Evidence)	 Face coverings are better than visors of face shields but if face coverings are not tolerated, visors or face shields may be used as an alternative Surgical masks are still only recommended to be used by healthcare providers Face coverings, visors, or face shields should not be used in place of isolation